NF-κB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145
Open Access
- 15 January 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 107 (2), 827-834
- https://doi.org/10.1182/blood-2005-05-1820
Abstract
NF-κB is a transcription factor that controls the expression of a number of genes important for mediating immune and inflammatory responses. In this study, we examined whether bortezomib and PS-1145, each of which inhibits NF-κB, could protect mice from lethal graft-versus-host disease (GVHD), which is characterized by immune activation and proinflammatory cytokine production. When administered within the first 2 days after transplantation, bortezomib and PS-1145 both protected mice from fatal GVHD, did not compromise donor engraftment, and effected marked reduction in the levels of serum cytokines that are normally increased during GVHD. Extending the course of bortezomib administration or delaying the initiation of this agent for as few as 3 days after bone marrow transplantation (BMT), however, significantly exacerbated GVHD-dependent mortality because of severe pathological damage in the colon. In contrast, prolonged administration of PS-1145, which, unlike bortezomib, is a selective inhibitor of NF-κB, caused no early toxicity and resulted in more complete protection than that observed with an abbreviated PS-1145 treatment schedule. These results confirm a critical role for NF-κB in the pathophysiology of GVHD and indicate that targeted inhibition of NF-κB may have a superior therapeutic index and may constitute a viable therapeutic approach to reduce GVHD severity. (Blood. 2006;107:827-834)Keywords
This publication has 49 references indexed in Scilit:
- Phase I Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study (ADVL0015)Journal of Clinical Oncology, 2004
- Phase II Trial of Bortezomib for Patients With Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2004
- Activation of Nuclear Factor κB In vivo Selectively Protects the Murine Small Intestine against Ionizing Radiation-Induced DamageCancer Research, 2004
- In vivo imaging of graft-versus-host-disease in miceBlood, 2004
- The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor BortezomibExperimental Cell Research, 2004
- The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cellsOncogene, 2003
- Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting CellsScience, 1999
- Structure, Regulation and Function of NF-kappaBAnnual Review of Cell Biology, 1994
- INTERLEUKIN-1 IS A CRITICAL EFFECTOR MOLECULE DURING CYTOKINE DYSREGULATION IN GRAFT VERSUS HOST DISEASE TO MINOR HISTOCOMPATIBILITY ANTIGENS1Transplantation, 1993
- Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.The Journal of Experimental Medicine, 1992